Case study shows that site activation is a key driver in determining patient enrollment cycle time, which can be minimized by identifying the "sweet spot" of sites to deploy for a clinical trial.
Karen Correa, PhD
Advertisement
Articles by Karen Correa, PhD
Case study demonstrates that site activation is a key driver in determining patient enrollment cycle time.
Advertisement
Latest Updated Articles
Enrollment Cycle Times Can and Should Be OptimizedPublished: January 17th 2018 | Updated:
- Enrollment Cycle Times Can and Should Be Optimized
Published: January 17th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
2
Honing the Power of AI for Next Generation Trial Oversight and Execution
3
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
4
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
